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1. Introduction 
Liver replacement is necessary for acute and chronic end stage liver failure and for 
correction of metabolic disorders. Even a temporary liver support is relevant under specific 
clinical conditions, giving cell based therapy a great potential. The decision on how much 
liver tissue should be replaced, depends on the degree of liver dysfunction and the chance of 
the native liver to recover. To minimize complications it is believed that the maximal 
percentage of engraftment that can be achieved is in the range of 2-5% of the host 
hepatocytes, whereas 10% are needed for an adequate support in liver failure. Several 
questions would still rise such as What is the best location for liver cell therapy? What kind 
of cells should be used? What strategy to increase cell engraftment should be employed? In 
this review we will discuss the experience gained with intravascular cell transplantation to 
the liver and future solutions using new technology for biomaterials production. We will 
expand on our experience with injectable hydrogel scaffold constructs consisting of 
PEGylated fibrinogen backbone and diacrylate (PEG-DA). The experience with their use for 
intravascular injection is still limited.  
Hepatocyte transplantation is a promising alternative method for the treatment of acute 
liver failure and also for the treatment of end stage liver disease. Hepatic cell transplantation 
can be used to temporarily gain time for acutely failing liver to recover, and to restore liver 
function in the chronic stage until a liver transplant becomes available. Transplanted 
hepatocytes can serve for the correction of congenital metabolic defects and for the transfer 
of genes by ex vivo gene therapy. The techniques used for cell transplantation may be 
implemented for other kinds of cells for therapy, including stem cells and immortalized- 
hepatocyte- cell lines. Other advantages of cell therapy over whole organ transplantation 
include the option to perform multiple hepatocyte transplantations in the same patient, and 
several patients could potentially be treated from one donor at a cost believed to be one 
tenth that of orthotopic liver transplantation. Studies have been undertaken to improve the 
methods related to hepatocyte transplantation, which include hepatocyte isolation from 
donor livers, cell culture propagation of the hepatocytes, hepatocyte preservation, and 
genetic modification of the hepatocytes to provide liver-specific functions and longevity. In 
humans, parenchymal hepatocytes isolated from donor livers remain the best cell source for 
transplantation, and other cell sources, including stem cells, are at the preclinical and early 
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clinical stages (Puppi et al. 2011). Major problems do not allow this method to be practical 
and these include the shortage of organs for cell recruitment and limitations in cell 
preservation. Moreover technical issues still exist. In rodents old reports suggested that 
transplanted cells into a normal host with normal liver architecture can integrate into the 
host liver and function for the long run but this was not proven to be the case (Ponder et 
al. 1991). New problems appeared when human studies were initiated, such as poor initial 
and long term engraftment and function. It was agreed in a recent consensus, that to 
obtain sufficient levels of repopulation of liver with donor cells in patients with metabolic 
liver disease, some form of liver preconditioning would be required to enhance the 
engraftment proliferation of donor cells (Puppi et al. 2011). Therefore the switch from the 
animal model to human studies in the set up of acute hepatic failure is not direct and the 
amount of cells to be transplanted based on animal studies is probably irrelevant to 
humans. Moreover, the time needed to reverse a failing human liver which is in the range 
of 3-6 months would be only a few days in the rodent model making issues of cell 
engraftment and long term function again irrelevant. What seems now to be the right 
volume of cells (2-5% of the hepatocytes), to be transplanted into the portal vein in the 
situation of acute hepatic failure in humans, can be later proven to be insufficient (Fisher 
and Strom. 2006). 
2. Which cell to transplant? 
The technique of cell transplantation in contrast to whole organ transplantation allows 
selecting the proper cells for transplantation as discussed in a recent review (Piscaglia et al. 
2010). For the purpose of treating the acutely failing organ adult parenchymal cells will be 
most suitable. These can be harvested from livers denied for transplantation or from non 
heart beating livers (Hughes et al. 2006; Mitry et al. 2004). Fetal parenchymal cells may be 
preferred due to their growth potential (Weber et al. 2010). Both sources of cells are of 
course limited. Harvesting cryopreserved cells may allow using cells when no immediate 
donor is available (Terry et al. 2007). The use of stem cells from embryonic source or from 
induced pluripotent stem cells as a source for hepatocytes is still remote from applicability. 
It may take long periods to expand and differentiate in culture, and the risk of tumor 
development always exists (Piscaglia et al. 2010). Xenotransplantation is also not applicable 
even though some experience was gained using porcine hepatocytes on a bioartificial liver 
device (Soto-Gutierrez et al. 2006). The fear of transferring infection always exists even 
though the immune response to transplanted cells seems lesser than to a whole organ (Rhim 
et al. 1994). 
2.1 Where to transplant  
The liver naturally is the ideal target organ for cell transplantation, in terms of the unique 
hepatic organization, interactions with non-parenchymal liver cells and biliary drainage. 
The spleen is also a viable target tissue for transplantation of hepatocytes since it offers the 
ability to form differentiated chord structures and reform nearly normal hepatic 
architectures (Mito et al. 1979). Hepatocytes transplanted to the spleen are responsive to 
liver regeneration stimuli after partial hepatectomy (Aoki et al. 2005). However, the infusion 
of cells into the portal system by the intra splenic route may be associated with portal vein 
thrombosis, liver necrosis, hemorrhage and portal and pulmonary hypertension. For 
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transplanted hepatocytes to engraft into the host liver and remain functionally viable over 
the long term, the most important outcome for these cells is to translocate from the portal 
pedicle into the liver microenvironment, as described by several groups (Ponder et al. 1991; 
Gupta et al. 1999). Another important limiting factor in utilizing either the intraportal or 
intrasplenic approach is the number of viable cells that can be engrafted without causing 
complications. It is believed that the maximal percentage of engraftment that can be 
achieved is in the range of 2-5% of the host hepatocytes whereas 10% are needed for an 
adequate support in liver failure (Sohlenius-Sternbeck. 2006; Asonuma et al. 1992). The first 
report on the intrasplenic transplantation via the intrasplenic arterial route was reported on 
patients with liver failure awaiting liver transplantation (Strom et al. 1999). Despite these 
complications and limitations, clinical trials of hepatocyte transplantation have been 
performed without causing any reported fatalities. The peritoneal cavity offers a large space 
for hepatocyte engraftment, and contact with portal flow but the peritoneal surface does not 
support long-term attachment and survival of liver cells. Attachment to collagen-coated 
beads or microencapsulation allowed for only minimal improvement (Selden et al. 2003; 
Baldini et al. 2008). Co transplantation with non parenchymal cells showed some promise 
yet, hepatocytes transplanted to the peritoneum or dorsal fat pad do not express genes as 
those transplanted in the liver (Gupta et al. 1994; Selden et al. 1995). To overcome the 
problems of intraportal transplantation in the advanced cirrhotic liver with portal 
hypertension, transplantation into an extrahepatic site is necessary. A strategy that allow 
repeated extrahepatic infusion of hepatocytes was tried, using a non-immunogenic self-
assembling peptide nanofiber. Developed as a three-dimensional scaffold and combined 
with growth factors, injected into the muscle of small animals, it resulted in improved 
hepatocytes function, but applicability to humans seems remote (Navarro-Alvarez et al. 
2010). 
2.2 The microenvironment 
Hepatocytes are the major cellular component of a bioartificial liver support system. 
Although they can elicit multiple functions by themselves, they depend on the cellular 
network of the non-parenchymal cells. The latter are major regulators of hepatocyte 
intermediary metabolism, growth and response to injury. Kupffer cells interact with 
hepatocytes to produce the acute-phase response , i.e., synthesis of C-reactive protein and 
alpha2-macroglobulin by IL-6. In –vitro, when Kupffer cells and hepatocytes are co-
cultured, the production of Nitric Oxide is enhanced (Billiar et al. 1990). Hepatocytes 
interact with hepatic stellate cells (fat storing cells, Ito cells, lipocytes) for the production of 
cellular matrix in vitro. Hepatic stellate cells proliferate, transform into myofibroblast like 
cells (“activated” hepatic stellate cells) and synthesize large amounts of extracellular matrix 
components (Collagens, fibronectin, tenascin, undulin, laminin and proteoglycans). 
Interaction with hepatocytes is mostly important for tissue remodeling. Myofibroblast like 
cells participate in the recruitment, activation and migration of inflammatory cells at sites of 
liver injury and play a role in regulating hepatic microcirculation. The endothelial cells that 
line the blood vessels and the space of Disse, have an important function in cytokine 
production and the synthesis of other molecules that support the microvasculature and 
microcirculation. The vascular growth and remodeling is very much dependent on growth 
factors and extracellular matrix components. A beneficial effect of co-transplantation with 
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non parenchymal cell has been shown before (Selden et al. 1995). When hepatocytes formed 
spheroids they kept their function within the matrices for a longer period of time (Lin and 
Bissell. 1993; Sakai et al. 2010). A recent paper described the beneficial effect for co-
transplantation in the peritoneum and the importance of spheroids structure is also stressed 
(Selden et al. 2003; Hamazaki et al. 2002; Torok et al. 2011). Bioartificial liver support 
systems incorporating nonparenchymal cells obtained better results in terms of both 
survival and function of hepatocytes. A method to prepare a biomatrix by a novel, four-step 
perfusion decellularization protocol using conditions designed to keep all collagen types 
insoluble, for repopulation, was reported recently (Wang et al. 2011). The various growth 
factors attached to the extra cellular matrix allowed for better differentiation of stem cells 
that repopulated the natural bioscaffold.  
3. Major growth factors involved in liver growth, regeneration and 
angiogenesis 
The knowledge obtained to date on liver cell growth and development during regeneration 
is very applicable to the development of liver tissue bioengineering for therapeutic 
strategies. Liver regeneration after partial hepatectomy is one of the most studied models for 
tissue regeneration medicine (Michalopoulos. 2010). We have learned that hepatocytes 
growth factor  (HGF), epidermal growth factor (EGF), transforming growth factor  α (TGFα) 
and TNFα/IL6 system are the most potent mitogens in vivo (Nakamura et al. 1987; 
Michalopoulos. 1990). Mainly nonparenchymal liver cells, such as hepatic stellate cells , and 
endothelial cells produce HGF (Schirmacher et al. 1992). During liver regeneration TGFα is 
secreted by both parenchymal and non-parenchymal liver cells.  TNFα and IL-6 family of 
cytokines were shown to have an important role in the regenerating liver as shown in knock 
out mice (Cressman et al. 1996). The proliferative and anti-apoptotic effect of these cytokines 
takes place only under special conditions such as those existing after partial hepatectomy 
(Streetz et al. 2000). Major inhibitors such as TGF beta, activin, p21 and p53, help regulate 
the regeneration process.  
Endothelial GFs: fibroblast GF (FGF) and vascular endothelial GF (VEGF) participate in liver 
regeneration (Assy et al. 1999). FGF is a potent endothelial GF and a primary liver mitogen. 
In its acidic form, aFGF makes hepatocytes more responsive to EGF and TGFa. The basic 
form is mitogenic to rat hepatocytes in vivo (Baruch et al. 1991; Baruch et al. 1995). bFGF, 
attached to macroaggregates, enhanced the engraftment of transplanted hepatocytes, by 
improving vascularization (Perets et al. 2003). FGF is mostly important also for the 
differentiation of stem cells into definitive endoderm (Kubo et al. 2004).VEGF has a wide 
range of activities; it increases the endothelial cells’ permeability, facilitates monocytes 
penetration, and enhances synthesis of plasminogen activator and plasminogen activator 
inhibitor in endothelial cells. VEGF has in addition a vasodilatatory effect mediated by nitric 
oxide. In the liver, receptors are found on endothelial cells and VEGF can be found in a 
small quantity within liver cells. It was reported that VEGF is released by both host and 
transplanted hepatocytes during cell entry into the liver plate (Slehria and Gupta. 1998). 
VEGF is secreted by replicating hepatocytes induce sinusoidal endothelial cell proliferation 
during regeneration after partial hepatectomy in rats. vWF translocates to sinusoidal 
endothelial cells during liver regeneration, a change that may have an important role in 
tissue remodeling during liver regeneration (Baruch et al. 2002).  
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4. Intravsacular cell based therapy and implantable constructs 
The most frequently applied hepatocyte transplantation method in humans is the injection 
of hepatocyte solution into the portal vein. This method, aimed to allow engraftment of 
hepatocytes within a defected liver, were used by Fox for the first time to treat a girl with 
Crigler Najar syndrome (Fox et al. 1998; Chowdhury et al. 1991). This method has the 
problems of insufficient cell survival and engraftment (Chowdhury et al. 1991; Grossman et 
al. 1995; Raper et al. 1996). Studies concerning cell injection into the spleen showed rapid 
translocation of transplanted cell through the spleen into the liver (Gupta et al. 1997). By 
using radio labeled cells it was demonstrated that cells were largely entrapped within the 
liver vascular bed and not entered the systemic circulation in normal animals (Gupta et al. 
1994; Ott and et al. 2002). Cell occlusion is due to mechanical mechanism, because the 
diameter of hepatocytes is 20-40 mm whereas that of the hepatic sinusoids is 6-9mm. The 
sinusoids can probably dilate up to the size of 40mm. The total volume of extracellular space 
is believed to be 15% of total liver volume. Due to this size difference, transplanted cells are 
deposited in the most proximal sinusoids, adjacent to the portal areas of the liver lobule 
(Gupta. 2002).While the number of cells passing through the sinusoids to the pulmonary 
circulation is less than 1% in the normal animal, in animals with portal hypertension and 
portosystemic collaterals even intra splenic injection results in 50% of heptocytes reaching 
the pulmonary circulation (Gupta et al. 1993). The vast majority of cells are destroyed 
instantaneously in the pulmonary capillaries possibly due to shear stress and some other 
mechanisms. These may include apoptosis and destruction by Kupffer cells secondary to 
possible ischemia reperfusion injury in this system, needing the use of vasodilators (Slehria 
et al. 2002). The transplanted cells occlude the hepatic sinusoids and the portal vein radicles, 
and portal hypertension is observed immediately. Interestingly the increased pressure is 
transient as was studied with albumin macroaggregates (Gupta et al. 1994). It is believed 
that the most common location for transplanted cells to engraft is the liver sinusoidal bed 
and manipulation to vasodilate the sinusoidal bed to improve engraftment was tried with 
some success (Slehria et al. 2002). We believe that once hepatocytes are in the sinusoids they 
will go all the way through, and those that remain and have the potential to engraft are 
those stacked in the portal radicles. This explains the very low transplantation efficiency on 
the one hand but on the other hand target the portal vein radicles as the site needs to be 
manipulated, rather than the sinusoidal bed. It is this site that probably allow for 
redistribution of blood after cell transplantation to reduce portal hypertension and to allow 
for transplanted cell aggregates to be included in the liver tissue. Therefore there is a 
rational for using angiogenic growth factors to accelerate this process and to allow better 
cellular engraftment (Shani-Peretz et al. 2005). We have used for this purpose VEGF and 
later Heparanase that on top of its angiogenic stimulation is capabale to release other 
growth factors from the injured liver that favor hepatocytes replication (Carmel et al. 2010; 
Tsiperson et al. 2008).  
It is quite clear that isolated cell transplantation by itself would not be enough and cell 
based strategies for temporary support systems for both extracorporeal and intra corporeal 
devices need special constructs (Navarro-Alvarez et al. 2010; Allen and Bhatia. 2002b). These 
devices include hepatocytes or hepatocytes derived cell lines in order to process patient 
plasma in the case of extracorporeal systems. Implantable tissue engineered constructs have 
also been developed for the purpose of long-term liver support (Allen and Bhatia. 2002a). 
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Construction of thicker tissues, was not possible due to limited diffusion of nutrients and 
oxygen within the engineered cell mass. It is known that cells can only survive within an 
area close enough to a source of nutrients and oxygen (Folkman and Hochberg. 1973; 
Rouwkema et al. 2008). Various techniques in polymer biochemistry and scaffold design to 
mimic the structure of this vascular network in engineered tissues were used. Strategies 
have included the co seeding of endothelial cells that spontaneously form capillary-like 
networks, and the engineering of branching channels to mimic the vascular tree.(Wang et al. 
2011; Kaihara et al. 2000). In addition, angiogenesis was induced in within engineered 
tissues by incorporating angiogenic peptides and growth factors into scaffolds and by 
engineering cells used in the organ constructs, to express these factors. However, these 
efforts have fallen short of producing scaffolds that contain a vascular tree with centralized 
inlet and outlet vessels that are suitable for transplantation and capable of nutrient and gas 
exchange. (Borselli et al. 2010). Scaffolds were fabricated from synthetic material that 
allowed micro-patterning of vascular tree-like structures. When growth factors are used 
alone, they tend to create only a microvasculature consisting of small and fragile capillaries, 
in a time consuming process, and therefore this technique is only applicable for the 
engineering of smaller size tissues (Perets et al. 2003). 
Development of implantable constructs with vasculature, remains a complicated challenge 
in terms of finding solutions for, the high metabolic rate of the liver cells, the need for 
unimpeded transport for large macromolecules and the need for cell-cell interaction (Dixit 
and Gitnick. 1995). In this respect, adult hepatocytes must interact with the various 
biomaterials, a process which is poorly understood and one of the key challenges to 
overcome in this field. Various hepatic tissue engineering approaches have been explored 
including the attachment of hepatocytes to microcarriers and encapsulated hepatocytes 
spheroids allowing for immunological protection and cell interaction (Demetriou et al. 
1986). Co transplantation is easier in within microcapsules that also have the advantage of 
immunological protection. The preferred site so far is the peritoneum that can accommodate 
large volume (Perets et al. 2003; Ambrosino et al. 2003; Teng et al. 2010; Shi et al. 2009; 
Mooney et al. 1997). Absorbing cells on biodegradable synthetic scaffolds to allow control 
over scaffold chemistry, and space for cell interaction and vascular growth was used (Perets 
et al. 2003; Mooney et al. 1997; Lee et al. 2009). A significant advancement in the field of 
bioscaffold design has been the utilization of decellularized liver tissue creating a three-
dimensional scaffold for tissue engineering strategies (Baptista et al. 2011). This study 
demonstrated that human liver cells can be seeded through the portal vein of a liver 
bioscaffold, and can be maintained in a specialized bioreactor with constant culture medium 
perfusion up to one week. Progressive human liver tissue formation was documented, as 
well as liver-associated functions. Widespread cell proliferation inside the bioengineered 
liver tissue with low cell apoptosis was also observed. These studies showed the possibility 
of seeding these bioscaffolds with liver cells from animals, but the possibility of generating 
functional human hepatic tissue is still in question.  
Cell encapsulation techniques their advantages and disadvantages are reviewed elsewhere 
(Hernandez et al. 2010). Recently, a biomaterial system developed that takes advantage of 
the biological properties of natural extracellular matrix proteins combined with precisely 
controllable properties of synthetic polymers for making scaffolds for tissue engineering 
(Almany and Seliktar. 2005; Seliktar. 2005). The biosynthetic hybrid biomaterials are ideally 
suitable for hepatic tissue engineering in that both the structure and function of the 
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construct can be exactly regulated by the compositional alterations to the biological and 
synthetic constituents of the material (Dikovsky et al. 2006; Underhill et al. 2007). These 
hybrids are made from extra cellular matrix proteins such as fibrinogen, collagen and 
albumin, while the synthetic polymer is made from polyethylene glycol (PEG) (Gonen-
Wadmany et al. 2007). The PEG constituent is biocompatible with liver cells and already 
received FDA approval. The PEGylated protein hydrogels have already been applied 
successfully in orthopedic applications and their biocompatibility has been established 
with 5-week implantation studies in rats. An additional advantage of the PEGylated 
protein approach is that the biomaterials are polymerizable using photo-initiation, which 
provide the ability to directly inject the biomaterial precursors solution together with 
hepatic cell suspension into the body and polymerize the construct in situ (Shapira-
Schweitzer and Seliktar. 2007). The combination of PEG and extra cellular matrix proteins 
in a PEGylated protein hydrogel system represents an advanced approach in scaffold 
design.  
These polymers have the advantage of size, shape and cell number control. Taking this 
advantage we have recently formed microcapsules at the size of 200-600 mm (Fig. 1). This 
size is injectable through a 25G syringe through the portal vain of rats. The injected 
microcapsules can protect groups of hepatocytes from shear stress and from passing 
through the sinusoids. These particles are stacked in the portal radicle allowing eventually 
for a group of cells to engraft into the host liver (Nayshool et al. ). 
 
 
Fig. 1. HUH7 cells encapsulated in a PEG-Fibrinogen hydrogel scaffold. Radius of 
microcapsules 100-200 micrometers 
In the long struggle against liver failure no one method would be most favorable. The 
strategy may be to employing different methods in the same individual and this would need 
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the optimization of each one of them. The intravascular route for encapsulated cells is a 
promising method, solving the problem of shear stress protection, oxygen and nutrient 
supply, and allow for planning ahead the cell type mixture for transplantation. Still, portal 
hypertension remain a problem that would need to be resolved. 
 
 
Fig. 2. HUH7 cells encapsulated in a PEG-Fibrinogen hydrogel scaffold in a portal radicle 
(H&E X40) 
 
Advantages Disadvantages 
Natural microenvironment Portal hypertension 
Linkage to bile system Portal vein thrombosis 
Relative large vascular space Distorted tissue in acute failure and cirrhosis 
Favorable regenerative tissue Cells bypass to the lungs 
 Insufficient space  
 Coagulation defects 
Table 1. The liver as the target 
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1. Use of Vasodilators. 
2. Combined use of angiogenic and proliferative growth factors. 
3. Control for the size of particles. 
4. Co-transplantation with non parenchymal cells. 
5. Liver preconditioning (partial hepatectomy, portal vein thrombosis, irradiation). 
6. Control the size of cell constructs 
 
Table 2. Strategies to improve cell engraftment within the liver 
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